Spyre Therapeutics (SYRE) Other Non Operating Income (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Other Non Operating Income data on file, last reported at -$30.4 million in Q1 2026.

• Quarterly Other Non Operating Income fell 1428.04% year-over-year to -$30.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 82.24% YoY) and the FY2025 annual result came in at $29.5 million, up 242.22% from the prior year.
• Other Non Operating Income retreated to -$30.4 million in Q1 2026, from -$12.5 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $40.3 million in Q3 2025 to a low of -$30.4 million in Q1 2026.
• A 5-year average of -$2.4 million and a median of -$72000.0 in 2023 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 9658.33% in 2023, down 66750.0% in 2023.
• Tracing SYRE's Other Non Operating Income over 5 years: stood at -$32000.0 in 2022, then plunged by 66750.0% to -$21.4 million in 2023, then surged by 96.18% to -$818000.0 in 2024, then tumbled by 1427.75% to -$12.5 million in 2025, then plunged by 142.93% to -$30.4 million in 2026.
• The last three Other Non Operating Income figures came in at -$30.4 million (Q1 2026), -$12.5 million (Q4 2025), and $40.3 million (Q3 2025), per Business Quant data.